Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall

Experimental Biology and Medicine

Volumn 235, Issue 3, 2010, Pages 311-316

  Gkizas, Spyridon I ^a   Apostolakis, Efstratios ^a   Pagoulatou, Eirini ^b   Mavrilas, Dimostenis ^b   Papachristou, Dionysios J ^a   Koletsis, Efstratios ^a   Papalois, Apostolos ^c   Papadaki, Helen ^a   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b Biomedical Engineering Laboratory   (Greece)

^c ELPEN Pharmaceuticals   (Greece)

Author keywords

Aldosterone receptors; Aortic wall mechanics; Cross links; Glycosaminoglycans; Proteoglycans

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; COLLAGEN FIBER; EPLERENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; BIOMECHANICS; CHOLESTEROL DIET; CONTROLLED STUDY; ELASTIC FIBER; HISTOPATHOLOGY; HYPERLIPIDEMIA; INTIMA; MALE; NONHUMAN; VISCOELASTICITY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; AORTA; BIOMECHANICS; BLOOD PRESSURE; DISEASE PROGRESSION; ELASTICITY; HYPERLIPIDEMIAS; MALE; RABBITS; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE; VISCOSITY;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 77950288875     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2009.009319     Document Type: Article

References (29)

1. Isselbacher EM. The normal aorta. In: Libby P, Bonow RO, Zipes DP, Mann DL, eds. Braunwald's Heart Disease. 8th edn, Part II. Philadelphia: Saunders-Elsevier, 2008:1457
2. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromsø Study. Am J Epidemiol 2001;154:236-244
3. Wilmink AB, Vardulaki KA, Hubbard CS, Day NE, Ashton HA, Scott AP, Quick CR. Are antihypertensive drugs associated with abdominal aortic aneurysms? J Vasc Surg 2002;36:751-757
4. Boyle J, Loftus IM, Goodall S, Crowther M, Bell PR, Thompson MM. Amlodipine potentiates metalloproteinase activity and accelerates elastin degradation in a model of aneurysmal disease. Eur J Vasc Endovasc Surg 1998;16:408-414
5. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix-metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Randomized aldactone evaluation study investigators: the effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
8. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-158
9. Fung YC. Biomechanics: Motion, Flow, Stress and Growth. New York: Springer-Verlag, 1990
10. Mavrilas D, Sinouris EA, Vynios DH, Papageorgakopoulou N. Dynamic mechanical characteristics of intact and structurally modified bovine pericardial tissues. J Biomech 2005;38:761-768
11. Li YY, Feldman AM. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs 2001;61:1239-1252
12. Klevay LM. Trace elements, atherosclerosis, and abdominal aneurysms. Ann NY Acad Sci 1996;800:239-242
13. Freestone T, Turner RJ, Higman DJ, Lever MJ, Powell JT. Influence of hypercholesterolemia and adventitial inflammation on the development of aortic aneurysm in rabbits, arteriosclerosis. Thrombosis Vasc Biol 1997;17:10-17
14. Hayashi K. Mechanical properties of soft tissues and arterial walls. In: Holzapfel GA, Ogden RW, eds. Biomechanics of Soft Tissue in Cardiovascular Systems. New York: Springer, 2003
15. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) study. Circulation 2009;119:2471-2479
16. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009;54:1674-1682
17. Diah S, Zhang GX, Nagai Y, Zhang W, Gang L, Kimura S, Hamid MR, Tamiya T, Nishiyama A, Hitomi H. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 2008;314:3654-3662
18. Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999;8:254-260
19. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008;51:432-439
20. Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, Lévy BI. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993;92:1407-1411
21. Corman B, Duriez M, Poitevin P, Heudes D, Bruneval P, Tedgui A, Levy BI. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 1998;95:1301-1306
22. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104:1464-1470
23. Bevan JA. Flow regulation of vascular tone. Its sensitivity to changes in sodium and calcium. Hypertension 1993;22:273-281
24. Bezie Y, Lamazière JM, Laurent S, Challande P, Cunha RS, Bonnet J, Lacolley P. Fibronectine expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1998;18:1027-1034
25. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats - effects of eplerenone. Circulation 2002;106:2848-2853
26. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-1800
27. Louis H, Li Z, Labat C, Lamaziere JM, Glucova M, Gardner H, Lacolley P. Defects in vascular smooth muscle hypertrophic response to angiotensin II in integrin alpha1 knockout mice. Hypertension 2004;43:1349 (abstract)
28. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats (SHRs). Arterioscler Thromb Vasc Biol 1997;17:1152-1156
29. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-667